Overview

Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether LLG783 displays the clinical safety and efficacy profile, after multiple i.v. doses, to support further development in patients with PAD and intermittent claudication.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals